Nicotinamide also reduced cell viability in prostate and oral cancers through Sirt1 and Sirt3 inhibition, respectively; however, the supra-physiological nicotinamide concentrations’ (5–40 mM) need to observe anti-cancer effects in these studies cast doubt on the therapeutic potential of nicotinamide in such models [204,205]. Here, SIRT1 is linked to cancer.